MA50636A - Compositions et procédés pour inhiber l'activité d'arginase - Google Patents

Compositions et procédés pour inhiber l'activité d'arginase

Info

Publication number
MA50636A
MA50636A MA050636A MA50636A MA50636A MA 50636 A MA50636 A MA 50636A MA 050636 A MA050636 A MA 050636A MA 50636 A MA50636 A MA 50636A MA 50636 A MA50636 A MA 50636A
Authority
MA
Morocco
Prior art keywords
arginase
inhibiting
compositions
activity
methods
Prior art date
Application number
MA050636A
Other languages
English (en)
Inventor
Jim Li
Eric B Sjogren
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MA50636A publication Critical patent/MA50636A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
MA050636A 2015-10-30 2016-10-28 Compositions et procédés pour inhiber l'activité d'arginase MA50636A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
MA50636A true MA50636A (fr) 2021-04-14

Family

ID=58631120

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43131A MA43131B1 (fr) 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase
MA050636A MA50636A (fr) 2015-10-30 2016-10-28 Compositions et procédés pour inhiber l'activité d'arginase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA43131A MA43131B1 (fr) 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase

Country Status (37)

Country Link
US (4) US10065974B2 (fr)
EP (3) EP3693375B1 (fr)
JP (3) JP6833844B2 (fr)
KR (2) KR102434308B1 (fr)
CN (4) CN108271371B (fr)
AU (3) AU2016343656B2 (fr)
BR (3) BR112018008746B1 (fr)
CA (1) CA3003271A1 (fr)
CL (4) CL2018001134A1 (fr)
CO (1) CO2018004750A2 (fr)
CR (3) CR20180282A (fr)
CY (1) CY1123557T1 (fr)
DK (2) DK3368541T3 (fr)
EA (1) EA038276B1 (fr)
EC (1) ECSP18040250A (fr)
ES (3) ES2991555T3 (fr)
HR (1) HRP20201046T1 (fr)
HU (1) HUE054972T2 (fr)
IL (3) IL258731B (fr)
LT (1) LT3368541T (fr)
MA (2) MA43131B1 (fr)
MD (1) MD3368541T2 (fr)
MX (1) MX2018005294A (fr)
MY (1) MY201783A (fr)
NZ (1) NZ742742A (fr)
PE (1) PE20181776A1 (fr)
PH (2) PH12022551082A1 (fr)
PL (1) PL3368541T3 (fr)
PT (1) PT3368541T (fr)
RS (1) RS60695B1 (fr)
SG (4) SG10201911406TA (fr)
SI (1) SI3368541T1 (fr)
SM (1) SMT202000469T1 (fr)
TW (3) TWI734630B (fr)
UA (1) UA125289C2 (fr)
WO (1) WO2017075363A1 (fr)
ZA (4) ZA201803556B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560978B1 (fr) 2010-04-22 2019-01-30 Mars, Incorporated Inhibiteurs d'arginase et leurs applications thérapeutiques
EP3034509B1 (fr) 2010-10-26 2020-04-22 Mars, Incorporated Inhibiteurs d'arginase en tant qu'agents thérapeutiques
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018119440A1 (fr) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions et procédés pour inhiber l'activité de l'arginase
KR20200008578A (ko) 2017-05-12 2020-01-28 칼리테라 바이오사이언시즈, 인코포레이티드 (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
WO2019173188A1 (fr) 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Inhibiteurs d'arginase
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
EP3810615B1 (fr) 2018-06-20 2026-01-28 Merck Sharp & Dohme LLC Inhibiteurs d'arginase et procédés d'utilisation
EP3880685B1 (fr) 2018-11-16 2025-06-18 Arcus Biosciences, Inc. Inhibiteurs d'arg1 et/ou d'arg2
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3897622B1 (fr) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Inhibiteurs d'arginase et procédés d'utilisation
CN113614095B (zh) * 2019-02-06 2024-08-23 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的烷基硼酸类化合物
PH12021552036A1 (en) * 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
EP4004004A1 (fr) * 2019-07-23 2022-06-01 AstraZeneca AB Inhibiteurs d'arginase et procédés d'utilisation associés
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CN118286450A (zh) 2019-11-12 2024-07-05 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021257857A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US20220041630A1 (en) 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
CA3211748A1 (fr) 2021-02-25 2022-09-01 Incyte Corporation Lactames spirocycliques utilises comme inhibiteurs du v617f de jak2
EP4313033A4 (fr) * 2021-03-24 2025-04-23 Trustees Of Tufts College Composés d'acide boronique, compositions et méthodes
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors
JP2025523364A (ja) * 2022-06-08 2025-07-23 デウン ファーマシューティカル カンパニー リミテッド アルギナーゼ阻害剤およびこれを含む薬学的組成物
WO2024086273A1 (fr) 2022-10-21 2024-04-25 Incyte Corporation Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2
WO2024191996A1 (fr) 2023-03-13 2024-09-19 Incyte Corporation Urées bicycliques utilisées en tant qu'inhibiteurs de kinase
WO2026076207A1 (fr) 2024-10-04 2026-04-09 Incyte Corporation Composés hétéroaryle tricycliques utilisés comme inhibiteurs de tyk2 et/ou de jak1
KR20260082235A (ko) * 2024-11-27 2026-06-04 주식회사 대웅제약 아르기나아제 저해제 및 이를 포함하는 약학적 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
WO2002004465A1 (fr) 2000-07-06 2002-01-17 Fal Diagnostics Procedes et trousses de detection de composes d'arginine
CA2431080A1 (fr) 2003-06-02 2004-12-02 Catherine Adele O'brien Amelioration de l'immunite contre le cancer par l'intermediaire de l'inhibition de l'arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (fr) 2003-08-07 2014-01-29 Allergan, Inc. Compositions d'administration d'agents therapeutiques dans les yeux
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (fr) 2005-07-01 2009-11-11 Univ Johns Hopkins Arginase ii: traitement ciblé du vieillissement cardiaque et de l'insuffisance cardiaque
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
US20110129456A1 (en) * 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
WO2010085797A2 (fr) * 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Inhibiteurs d'arginase et leurs méthodes d'utilisation
EP2560978B1 (fr) * 2010-04-22 2019-01-30 Mars, Incorporated Inhibiteurs d'arginase et leurs applications thérapeutiques
EP3034509B1 (fr) * 2010-10-26 2020-04-22 Mars, Incorporated Inhibiteurs d'arginase en tant qu'agents thérapeutiques
RU2019121905A (ru) 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
CA2852685C (fr) 2011-10-19 2019-02-26 Mars, Incorporated Inhibiteurs d'arginase et leur application therapeutique
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
SG11201503459SA (en) * 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
WO2015061752A1 (fr) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
KR20170129896A (ko) * 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
EA038276B1 (ru) 2021-08-04
US10065974B2 (en) 2018-09-04
US10844080B2 (en) 2020-11-24
JP6833844B2 (ja) 2021-02-24
PL3368541T3 (pl) 2020-11-02
CN113150015A (zh) 2021-07-23
LT3368541T (lt) 2020-09-25
TW202110858A (zh) 2021-03-16
CN108271371B (zh) 2021-02-09
PT3368541T (pt) 2020-07-06
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
EA201891057A1 (ru) 2018-12-28
BR122020022280B1 (pt) 2022-05-03
JP2018533582A (ja) 2018-11-15
HUE054972T2 (hu) 2021-10-28
CL2019000820A1 (es) 2019-08-09
EP3368541A1 (fr) 2018-09-05
MD3368541T2 (ro) 2020-09-30
KR20220118559A (ko) 2022-08-25
CN113150016A (zh) 2021-07-23
CL2019000819A1 (es) 2019-08-09
UA125289C2 (uk) 2022-02-16
ES2910928T3 (es) 2022-05-17
IL258731A (en) 2018-06-28
SG10201911402YA (en) 2020-02-27
ES2808988T3 (es) 2021-03-02
US20210061822A1 (en) 2021-03-04
HRP20201046T1 (hr) 2020-10-16
PH12018500899A1 (en) 2018-10-29
EP3368541A4 (fr) 2019-07-17
US10851118B2 (en) 2020-12-01
MX2018005294A (es) 2018-09-21
CR20210390A (es) 2021-10-19
SG11201802961PA (en) 2018-05-30
IL258731B (en) 2021-04-29
CY1123557T1 (el) 2022-03-24
AU2016343656B2 (en) 2020-09-17
CO2018004750A2 (es) 2018-10-31
CL2018001134A1 (es) 2018-10-26
EP3693375B1 (fr) 2022-02-16
CR20180282A (es) 2018-11-30
TWI775556B (zh) 2022-08-21
JP2021075543A (ja) 2021-05-20
MY201783A (en) 2024-03-18
CN108271371A (zh) 2018-07-10
PH12018500899B1 (en) 2023-02-08
TW202146028A (zh) 2021-12-16
DK4011887T3 (da) 2024-10-28
JP2022071010A (ja) 2022-05-13
KR102434308B1 (ko) 2022-08-19
TWI734630B (zh) 2021-07-21
ZA201907093B (en) 2021-03-31
CR20210389A (es) 2021-09-16
EP4011887B1 (fr) 2024-07-31
MA43131B1 (fr) 2020-07-29
AU2020286278B2 (en) 2022-03-17
BR112018008746A8 (pt) 2019-02-26
EP4011887A1 (fr) 2022-06-15
AU2020286278A1 (en) 2021-01-14
PH12022551082A1 (en) 2023-03-13
ZA201907091B (en) 2021-05-26
US20170121352A1 (en) 2017-05-04
JP7032583B2 (ja) 2022-03-08
US20200223872A1 (en) 2020-07-16
RS60695B1 (sr) 2020-09-30
PE20181776A1 (es) 2018-10-31
WO2017075363A1 (fr) 2017-05-04
TWI710565B (zh) 2020-11-21
ES2991555T3 (es) 2024-12-04
CL2019000821A1 (es) 2019-08-09
IL281503B (en) 2022-01-01
ZA201907092B (en) 2021-04-28
IL281503A (en) 2021-04-29
US20180346489A1 (en) 2018-12-06
IL288225A (en) 2022-01-01
BR122020022275B1 (pt) 2022-05-03
EP3693375A1 (fr) 2020-08-12
ZA201803556B (en) 2021-02-24
AU2022203703A1 (en) 2022-06-16
CN113201002A (zh) 2021-08-03
SI3368541T1 (sl) 2020-10-30
AU2016343656A1 (en) 2018-06-07
ECSP18040250A (es) 2018-10-31
BR112018008746A2 (pt) 2018-10-30
TW201726692A (zh) 2017-08-01
SG10201911406TA (en) 2020-01-30
BR112018008746B1 (pt) 2021-11-16
CA3003271A1 (fr) 2017-05-04
EP3368541B1 (fr) 2020-05-27
SMT202000469T1 (it) 2020-11-10
HK1252560A1 (en) 2019-05-31
DK3368541T3 (da) 2020-06-29
KR20180084063A (ko) 2018-07-24

Similar Documents

Publication Publication Date Title
EP3368541A4 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
IL267532B (en) Preparations and methods for inhibiting arginase activity
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
EP3325017A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3386484A4 (fr) Compositions et procédés permettant d'administrer des agents thérapeutiques
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
EP3273944A4 (fr) Compositions et procédés permettant d'administrer des agents de type biomacromolécule
EP3386550A4 (fr) Procédés et compositions pour la fabrication et l'utilisation d'acides nucléiques de guidage
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA41253A (fr) Composés, compositions et procédés pour augmenter l'activité du cftr
EP3359693A4 (fr) Procédés et compositions pour enrichissement de produits d'amplification
EP3267995A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose
EP3289064A4 (fr) Compositions et procédés pour la détection d'allergènes
EP3349743A4 (fr) Procédés et compositions d'inhibition de l'interaction dcn1-ubc12
EP3302558A4 (fr) Agents anticancéreux et procédés d'utilisation
EP3373950A4 (fr) Procédés et compositions d'évaluation de spécificités d'anticorps
EP3488018A4 (fr) Procédés et compositions pour l'identification de protéines
EP3389673A4 (fr) Procédés et compositions pour l'administration de polynucléotides
EP3458448A4 (fr) Procédés d'utilisation d'inhibiteurs de fasn
EP3261631A4 (fr) Inhibition de l'activité d'olig2
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants